Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UF-KURE-BCMA CAR T-cells
- Development stage
- Phase 1
- Lead developer
- University of Florida
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UF-KURE-BCMA CAR T-cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed for the treatment of relapsed or refractory multiple myeloma. This therapy uses a patient’s own CD4-positive and CD8-positive T cells, which are genetically engineered ex vivo using a novel ultrafast lentiviral manufacturing system to express a humanized anti-B-cell maturation antigen (BCMA) chimeric antigen receptor. The process allows for rapid production from simple peripheral blood draws rather than invasive leukapheresis, with manufacturing times significantly shorter than standard FDA-approved CAR-T therapies. After genetic modification and expansion, the modified T cells are infused back into the patient following lymphodepleting chemotherapy to target and eliminate BCMA-expressing multiple myeloma cells[1][2][3].
- Brand names
- UF-KURE-BCMA CAR T-cells
- Other names
- UF-KURE-BCMAUF-KURE-BCMA CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on UF-KURE-BCMA CAR T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UF-KURE-BCMA CAR T-cells.